Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105

Benzinga · 2d ago
Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.